Dolutegravir + Abacavir + Lamivudine 600/50/300mg
| Product Overview |
| Generic Name | Dolutegravir + Abacavir + Lamivudine 600/50/300mg |
| Brand Name(s) | Triumeq |
| Form | 30 Film-coated oral tablets |
| Strength | 600 mg abacavir / 50 mg dolutegravir / 300 mg lamivudine per tablet |
| Therapeutic Class | Integrase strand transfer inhibitor (dolutegravir) + 2 NRTIs (abacavir, lamivudine) |
| ATC Code | J05AR13 |
| Manufacturing & Regulatory |
| Manufacturer | ViiV Healthcare; Varios generic mfgs |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP for generics |
| DMF/CEP | type II |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export |
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 30°C Protect from moisture and light. Do not refrigerate or freeze. |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Indications & Usage: Triumeq is indicated for the treatment of HIV‑1 infection in patients (adults/adolescents ≥25 kg), combining an integrase inhibitor plus two NRTIs in a single, once-daily tablet. It reduces HIV viral load and is suitable for both treatment-naïve and experienced patients without resistance.
Request for Quote
